• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert Review of Molecular Diagnostics >Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.
【24h】

Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.

机译：胰腺导管腺癌基于miRNA的诊断检测方法的开发。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diagnosis of pancreatic cancer remains a clinical challenge. Both chronic pancreatitis and pancreatic cancer may present with similar symptoms and similar imaging features, often leading to incorrect interpretation. Thus, the use of an objective molecular test that can discriminate between chronic pancreatitis and pancreatic cancer will be a valuable asset in obtaining a definitive diagnosis of pancreatic cancer. Following Clinical Laboratory Improvement Amendments and College of American Pathologists guidelines, Asuragen Clinical Services Laboratory has developed and validated a laboratory-developed test, miRInform((R)) Pancreas, to aid in the identification of pancreatic ductal adenocarcinoma. This molecular diagnostic tool uses reverse-transcription quantitative PCR to measure the expression difference between two miRNAs, miR-196a and miR-217, in fixed tissue specimens. This article describes the test validation process as well as determination of performance parameters of miRInform Pancreas.
机译：胰腺癌的诊断仍然是临床挑战。慢性胰腺炎和胰腺癌都可能表现出相似的症状和相似的影像学特征，通常会导致错误的解释。因此，使用能够区分慢性胰腺炎和胰腺癌的客观分子测试将是获得权威性胰腺癌诊断的宝贵资产。按照临床实验室改进修正案和美国病理学家学院的指导方针，阿修罗根临床服务实验室已经开发并验证了实验室开发的胰腺胰腺癌检测（miRInform（R）），以帮助鉴定胰腺导管腺癌。该分子诊断工具使用逆转录定量PCR来测量固定组织样本中两个miR-196a和miR-217之间的表达差异。本文介绍了miRInform胰腺的测试验证过程以及性能参数的确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号